We are a profitable and growing company focused on the acquisition, development and commercialization of branded prescription products for specialty physician market segments. Since our inception in 1999, we have successfully funded the acquisition and development of our product portfolio with limited external investment, and have been profitable since 2004. We believe we have significant growth opportunities with our existing product portfolio and we continue to identify and pursue other promising product candidates. Source
No articles found.
Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical compa...
Recro Pharma (NASDAQ: REPH) is a revenue genera...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Fellazo Inc. is a newly incorporated blank check company incorporated as a Cayman ...
Fellazo Inc. is a newly incorporated blank chec...
Join the National Investor Network and get the latest information with your interests in mind.